PL3352742T3 - Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona - Google Patents

Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona

Info

Publication number
PL3352742T3
PL3352742T3 PL16848274T PL16848274T PL3352742T3 PL 3352742 T3 PL3352742 T3 PL 3352742T3 PL 16848274 T PL16848274 T PL 16848274T PL 16848274 T PL16848274 T PL 16848274T PL 3352742 T3 PL3352742 T3 PL 3352742T3
Authority
PL
Poland
Prior art keywords
disease
triterpenoids
parkinson
alzheimer
compositions
Prior art date
Application number
PL16848274T
Other languages
English (en)
Inventor
Zadik Hazan
Konstantin Adamsky
Andre C. B. Lucassen
Nurit NOVAK
Original Assignee
Angels Hi-Tech Investment Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angels Hi-Tech Investment Company filed Critical Angels Hi-Tech Investment Company
Publication of PL3352742T3 publication Critical patent/PL3352742T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PL16848274T 2015-09-24 2016-09-22 Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona PL3352742T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222976P 2015-09-24 2015-09-24
PCT/IL2016/051057 WO2017051423A1 (en) 2015-09-24 2016-09-22 Compositions comprising triterpenoids
EP16848274.3A EP3352742B1 (en) 2015-09-24 2016-09-22 Compositions comprising triterpenoids for the treatment of alzheimer's disease and parkinson's disease

Publications (1)

Publication Number Publication Date
PL3352742T3 true PL3352742T3 (pl) 2022-05-16

Family

ID=58386370

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16848274T PL3352742T3 (pl) 2015-09-24 2016-09-22 Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona

Country Status (13)

Country Link
US (3) US10285996B2 (pl)
EP (1) EP3352742B1 (pl)
JP (1) JP7031867B2 (pl)
KR (1) KR20180053406A (pl)
CN (1) CN108289863B (pl)
AU (1) AU2016327288A1 (pl)
CA (1) CA2999822A1 (pl)
DK (1) DK3352742T3 (pl)
ES (1) ES2904263T3 (pl)
HK (1) HK1257366A1 (pl)
IL (1) IL258279B (pl)
PL (1) PL3352742T3 (pl)
WO (1) WO2017051423A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565580A (zh) * 2017-12-28 2020-08-21 三得利控股株式会社 用于抑制活性氧产生的组合物
KR102583195B1 (ko) * 2020-12-10 2023-09-26 경상국립대학교산학협력단 퀴노바산을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
CN115501261B (zh) * 2022-10-14 2023-09-22 山西大学 一种藜麦糠水溶性萜类提取物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361863A2 (en) 2001-02-13 2003-11-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Carotenoid-loaded liposomes
EP1501527B1 (en) 2002-05-01 2009-09-02 Lavipharm S.A. Use of mastic and its essential oils for the control of microbial infections
FR2867980B1 (fr) 2004-03-23 2006-07-14 Pierre Fabre Medicament Sa Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta
WO2005112967A2 (en) 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
GB2474813B (en) * 2008-09-19 2014-05-28 Biotechnology Res Corp Ltd Triterpenoid compounds and methods of use thereof
TR201911270T4 (tr) * 2009-03-04 2019-08-21 Regenera Pharma Ltd Polimerik mirsen bileşimleri.
DK2403505T3 (en) * 2009-03-04 2017-03-06 Regenera Pharma Ltd Therapeutic Applications of Mastic Rubber Fractions
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
PL2613777T3 (pl) * 2010-09-07 2019-10-31 Regenera Pharma Ltd Kompozycje zawierające kwasowe ekstrakty mastyksu
CN104105722B (zh) * 2011-12-14 2016-11-09 英尼奥斯欧洲股份公司 聚合物
CN103360456B (zh) * 2012-04-04 2015-07-29 浙江大学 三萜类化合物及制备和应用
US9114130B2 (en) * 2013-05-06 2015-08-25 University Of South Florida Compounds and related methods for treatment of neurodegenerative diseases
CN104910238B (zh) * 2014-03-14 2017-08-11 中国科学院上海药物研究所 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途

Also Published As

Publication number Publication date
JP2018528973A (ja) 2018-10-04
JP7031867B2 (ja) 2022-03-08
EP3352742A4 (en) 2019-05-15
CA2999822A1 (en) 2017-03-30
HK1257366A1 (zh) 2019-10-18
CN108289863A (zh) 2018-07-17
US11173164B2 (en) 2021-11-16
CN108289863B (zh) 2021-03-16
EP3352742B1 (en) 2021-11-03
IL258279A (en) 2018-05-31
US10588911B2 (en) 2020-03-17
WO2017051423A1 (en) 2017-03-30
US20190209582A1 (en) 2019-07-11
AU2016327288A1 (en) 2018-04-12
US10285996B2 (en) 2019-05-14
IL258279B (en) 2022-09-01
KR20180053406A (ko) 2018-05-21
ES2904263T3 (es) 2022-04-04
DK3352742T3 (da) 2022-01-10
US20180264006A1 (en) 2018-09-20
EP3352742A1 (en) 2018-08-01
US20200155569A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL268406A (en) Preparations and methods for treating hemoglobin diseases
IL260257A (en) Preparations and methods for the treatment of hemoglobinopathies
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
IL260352B (en) Methods and preparations for the treatment of neurological disease
IL266047A (en) Methods and preparations for the treatment of Fabry disease
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
IL263188B (en) Treatment for Parkinson's disease
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
IL274588A (en) Methods and preparations for improving lysosome function and treating neurodegenerative disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
AU2015904411A0 (en) Compositions and methods for the treatment of Alzheimer's disease
ZA201807944B (en) Treatment for parkinson's disease
HK40012465A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
GB201511453D0 (en) Treatment of alzheimer's disease